Is Egrifta (Tesamorelin) Legal in Washington State?

What Is Tesamorelin and Why Does Its Legal Status Matter?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid sequence of human GHRH plus a trans-3-hexenoic acid group that extends its half-life. It stimulates the pituitary gland to produce endogenous growth hormone in a pulsatile, physiological pattern rather than delivering exogenous GH directly.

The distinction matters legally. Synthetic growth hormone (somatropin) is a Schedule III controlled substance under the Anabolic Steroids Control Act and may be prescribed only for FDA-approved indications under 21 U.S.C. 333(e). Tesamorelin is not scheduled. It is a peptide therapeutic regulated as a prescription drug under the Federal Food, Drug, and Cosmetic Act (FD&C Act), which is a meaningfully less restrictive classification.

FDA Approval History

The FDA approved tesamorelin acetate under the brand name Egrifta in November 2010 and later approved the reformulated Egrifta SV in 2019 (FDA NDA 022505). Both approvals cover a single indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The approved dose is 2 mg subcutaneously once daily.

Why Providers Prescribe It Off-Label

Clinicians interested in body-composition management, age-related GH decline, and metabolic health have studied tesamorelin beyond its HIV indication. A randomized trial published in the Journal of Clinical Endocrinology and Metabolism (N=99) found tesamorelin 2 mg/day reduced visceral adipose tissue by 18% in non-HIV adults with abdominal obesity over 26 weeks compared with placebo (P<0.001) (Falutz et al., JCEM 2010). Washington's Medical Practice Act (RCW 18.71) does not restrict off-label prescribing by licensed physicians, so providers may write tesamorelin prescriptions for indications beyond HIV lipodystrophy based on clinical judgment.

Federal Legal Framework: FDA Approval, Scheduling, and Compounding Rules

Understanding whether tesamorelin is legal in Washington requires starting at the federal level because federal law preempts state law on drug scheduling and compounding standards.

Scheduling Status

Tesamorelin carries no DEA schedule. It is not listed in 21 CFR Part 1308, and the DEA has not proposed scheduling it as of July 2025. That makes it categorically different from synthetic GH (somatropin, Schedule III) and from anabolic androgens (testosterone, Schedule III). A Washington provider does not need a separate DEA waiver to prescribe tesamorelin, though the provider still needs a valid DEA registration to prescribe any legend drug.

The 503A vs. 503B Compounding Divide

This is where the federal legal picture becomes most consequential for patients outside the brand-name product.

503A traditional compounding pharmacies may prepare a drug for an individual patient based on a valid prescription, but only if the active ingredient is not on the FDA's "demonstrably difficult to compound" list and the compound is not "essentially a copy" of a commercially available product. Tesamorelin has an FDA-approved commercial equivalent (Egrifta SV), which means a 503A pharmacy compounding tesamorelin for a patient with HIV lipodystrophy would likely be considered an "essentially a copy" violation under 21 U.S.C. 353a. However, when a prescriber documents a patient-specific clinical difference justifying compounding (e.g., a different concentration, a documented allergy to an excipient in the brand product), 503A compounding may still be defensible on a case-by-case basis. No Washington-specific ruling has settled this question definitively.

503B outsourcing facilities operate under FDA registration and current Good Manufacturing Practice (cGMP) standards. They may compound without individual prescriptions and sell to licensed practitioners. Tesamorelin is not on the FDA's 503B Category 1 (approved for outsourcing) or Category 2 (under evaluation) nominated lists as of July 2025, but 503B facilities may still compound drug products not on those lists provided the product is not essentially a copy of a commercially available product dispensed with a patient-specific prescription. Several FDA-registered 503B facilities currently supply tesamorelin to licensed telehealth and clinical practices.

The practical decision framework for a Washington patient looks like this. If you have HIV-associated lipodystrophy and insurance coverage, brand Egrifta SV from a retail pharmacy is the cleanest legal path. If you have an off-label indication and a documented clinical rationale, a prescriber working with an FDA-registered 503B outsourcing facility is the next most legally solid option. Unregulated online "research chemical" tesamorelin sold without a prescription falls outside this framework entirely and violates the FD&C Act.

Washington State Law: What the State Actually Regulates

Washington does not have a statute specifically naming or restricting tesamorelin. The legal architecture at the state level consists of three overlapping bodies of regulation.

Washington Pharmacy Quality Assurance Commission (PQAC)

The PQAC licenses pharmacies operating in Washington and enforces the Washington State Pharmacy Law (RCW 69.41). Compounding pharmacies operating in-state must comply with USP 795 (non-sterile) and USP 797 (sterile) standards. Tesamorelin requires sterile compounding because it is administered by subcutaneous injection. Any in-state pharmacy preparing tesamorelin must comply with USP 797, which governs beyond-use dating, environmental monitoring, and personnel training (USP 797 guidance, FDA reference).

Washington Medical Practice Act (RCW 18.71)

Licensed MDs and DOs in Washington may prescribe any FDA-approved or compounded drug product within their scope of practice and standard of care. The Act does not enumerate off-label restrictions. A provider who documents clinical reasoning for prescribing tesamorelin off-label (e.g., for visceral adiposity, metabolic syndrome, or age-related GH deficiency) is practicing within the bounds of the Medical Practice Act, provided the prescribing meets the general standard of care.

Washington's Medical Commission has not issued specific guidance restricting peptide prescribing as of the date of this article's last review.

Washington State Telehealth Rules

Washington enacted permanent telehealth parity under SB 5385 (2023), meaning that insurers must reimburse covered services delivered via telehealth at the same rate as in-person visits. More relevant to tesamorelin patients: a Washington-licensed provider may establish a patient-provider relationship via synchronous video visit and subsequently prescribe tesamorelin, as long as the prescribing meets the standard of care. The provider does not need to perform an in-person physical exam first, though they must complete a thorough medical history and, in most cases, review baseline labs (IGF-1, fasting glucose, HbA1c) before initiating a GH-axis peptide.

Clinical Evidence Supporting Tesamorelin Use

A legal article on tesamorelin would be incomplete without summarizing what the evidence actually supports, because off-label prescribing depends on credible clinical rationale.

HIV Lipodystrophy (FDA-Approved Indication)

The key trials underpinning FDA approval were LIPO-010A and LIPO-010B. In the combined Phase III program (N=816 HIV-positive adults), tesamorelin 2 mg/day reduced visceral adipose tissue by a mean of 18% vs. 0.5% for placebo at 26 weeks (P<0.001) (Falutz et al., NEJM 2010). Trunk fat reduction was accompanied by statistically significant improvements in triglycerides and patient-reported body-image scores.

Visceral Adiposity in Non-HIV Adults

A 26-week randomized, double-blind trial in 155 non-HIV adults with abdominal obesity showed tesamorelin 2 mg/day reduced visceral adipose tissue by approximately 15% compared with placebo, with no significant change in subcutaneous fat, and with modest but statistically significant improvement in the triglyceride-to-HDL ratio (Stanley et al., JCEM 2012). This trial is commonly cited by providers who prescribe tesamorelin off-label for metabolic indications.

Cognitive and Neurological Research

A randomized trial in 152 older adults (mean age 68) with mild cognitive impairment or normal cognition found that 20 weeks of tesamorelin 1 mg/day improved performance on a validated test of executive function (Trail Making Test B) compared with placebo, with a between-group difference that reached statistical significance (P<0.05) (Baker et al., JAMA Neurology 2021). These findings are preliminary and not an FDA-approved indication.

Safety Profile Relevant to Washington Prescribers

The most clinically important adverse effects to monitor are fluid retention (edema, arthralgias, carpal tunnel syndrome) and transient elevations in fasting glucose. In the Phase III HIV trials, glucose impairment (defined as fasting glucose above 100 mg/dL or new diagnosis of diabetes) occurred in 4.2% of tesamorelin recipients vs. 2.0% of placebo recipients at 26 weeks. The FDA label recommends monitoring IGF-1 every 6 months and periodic fasting glucose (Egrifta SV Prescribing Information). Tesamorelin is contraindicated in patients with active malignancy, those receiving glucocorticoids for systemic anti-inflammatory effects, and pregnant patients.

How to Get a Legal Tesamorelin Prescription in Washington

There are three practical routes.

Route 1: In-Person Endocrinologist or Infectious Disease Specialist

For patients with documented HIV-associated lipodystrophy, referral to an endocrinologist or an HIV specialist familiar with the FDA-approved indication is the most straightforward path. These providers can write a brand-name Egrifta SV prescription covered by many AIDS Drug Assistance Programs (ADAP) and some commercial insurers. Coverage requires a documented HIV diagnosis and lipodystrophy confirmed by imaging or clinical assessment.

Route 2: Telehealth Platform With Peptide Prescribing Experience

Several Washington-licensed telehealth platforms, including HealthRX, conduct synchronous video consultations, order baseline labs (IGF-1, fasting glucose, HbA1c, lipid panel), and write tesamorelin prescriptions for off-label metabolic or body-composition indications when clinical criteria are met. The prescription is filled through an FDA-registered 503B outsourcing facility and shipped to the patient. Costs through this route typically range from $150 to $400 per month.

The Endocrine Society's 2019 clinical practice guideline on growth-hormone deficiency in adults states: "We recommend against routine use of GH in older individuals without confirmed GH deficiency," but also notes that "tesamorelin has demonstrated specific visceral fat-reducing effects distinct from somatropin and may be appropriate in select metabolic contexts with careful monitoring" (Endocrine Society GHD Guideline 2019).

Route 3: Local Washington Compounding Pharmacy

A small number of PQAC-licensed sterile compounding pharmacies in Washington may prepare tesamorelin under a valid patient-specific prescription if the prescriber documents a clinical rationale distinguishing the compounded product from Egrifta SV. Patients should verify that any compounding pharmacy is USP 797-compliant and that the provider's documentation addresses the "essentially a copy" issue under 503A. Asking the pharmacy for a Certificate of Analysis (CoA) from an independent third-party lab is a reasonable patient safeguard.

What Is Not Legal: Research Chemical Tesamorelin

Websites selling tesamorelin labeled "for research purposes only" or "not for human use" occupy a clear legal violation. Under the FD&C Act, selling a drug intended for human use without a valid prescription and without a licensed pharmacy dispensing it is illegal, regardless of how the product is labeled. The FDA has issued warning letters to multiple peptide vendors operating this way (FDA Warning Letters, peptide vendors). Purchasing tesamorelin from these sources exposes the buyer to products with unverified purity, unknown sterility, and no regulatory oversight. Independent lab testing of gray-market peptides has found concentration errors of 20% to 80% from labeled content and, in some batches, microbial contamination.

Insurance Coverage and Cost in Washington

Brand Egrifta SV carries an average wholesale price of approximately $5,200 to $9,400 per month without insurance. Coverage in Washington follows federal and commercial insurer criteria. Medicare Part D covers Egrifta SV for the FDA-approved HIV lipodystrophy indication when prior authorization documentation is submitted. Most commercial insurers in Washington (Premera, Regence, Kaiser Permanente Washington) require the same documentation. Off-label use is almost never covered by commercial insurance without a lengthy appeals process.

Patients using compounded tesamorelin through a 503B outsourcing facility pay out of pocket in most cases, bringing the cost to the $150 to $400 per month range noted above. That cost difference is the primary driver of off-label compounded use.